Stock Events

Stock Events

Dynavax Technologies

€9.59

104

-€0.03-0.29% Friday 13:29

Statistics

Day High

9.59

Day Low

9.49

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

1.36B

P/E Ratio

166.17

Dividend Yield

-

Dividend

-

Earnings

8MayConfirmed

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-0.19

0.02

0.24

0.45

Expected EPS

-0.02

Actual EPS

-0.07

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DYF1.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Novavax is a direct competitor in the vaccine development space, particularly for COVID-19, where both companies have significant investments.

Moderna is a leader in mRNA vaccine technology, competing with Dynavax's adjuvant technology in developing vaccines for infectious diseases.

Pfizer, with its broad portfolio including COVID-19 vaccines, competes in the same market as Dynavax, especially in vaccine development and distribution.

Johnson & Johnson

Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the vaccine market, including COVID-19, where Dynavax also operates.

GlaxoSmithKline competes with Dynavax in the development of vaccines, including their adjuvant systems used to enhance vaccine efficacy.

Sanofi competes in the vaccine market, including flu vaccines, where Dynavax also has products, making them direct competitors.

AstraZeneca competes with Dynavax in the COVID-19 vaccine space, among other areas, making them significant competitors in pandemic response efforts.

BioNTech, in partnership with Pfizer, competes directly with Dynavax in the COVID-19 vaccine market, leveraging mRNA technology.

CureVac competes in the mRNA vaccine space, similar to Dynavax's involvement in vaccine technology, particularly for infectious diseases.

VBI Vaccines competes with Dynavax in the development of hepatitis B vaccines, among other infectious diseases, making them direct competitors in specific vaccine markets.

About

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Show more...

CEO

Mr. Ryan Spencer

Employees

408

Country

US

ISIN

US2681582019

WKN

000A12EV9

Listings